Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome.
about
A Case Based Approach to Clinical Genetics of Thoracic Aortic Aneurysm/Dissection.Marfan syndrome: current perspectivesHereditary Influence in Thoracic Aortic Aneurysm and Dissection.The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutationsDiagnosis and Management of Thoracic Aortic Disease.Genetic testing in Marfan syndrome.Marfan Syndrome and Related Disorders: 25 Years of Gene Discovery.Ruptured abdominal aortic aneurysm-epidemiology, predisposing factors, and biology.Vascular smooth muscle cells in Marfan syndrome aneurysm: the broken bricks in the aortic wall.Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse ModelGenotype impacts survival in Marfan syndrome.Molecular Outcome, Prediction, and Clinical Consequences of Splice Variants in COL1A1, Which Encodes the proα1(I) Chains of Type I Procollagen.Therapeutics Targeting Drivers of Thoracic Aortic Aneurysms and Acute Aortic Dissections: Insights from Predisposing Genes and Mouse Models.Strategies to prevent aortic complications in Marfan syndrome.Editorial Commentary: Understanding Marfan syndrome, or "how not to invent the light bulb".Impaired Central Pulsatile Hemodynamics in Children and Adolescents With Marfan Syndrome.Medical management of aortic disease in Marfan syndrome.Crossing Bridges between Extra- and Intra-Cellular Events in Thoracic Aortic Aneurysms.The importance of genotype-phenotype correlation in the clinical management of Marfan syndrome.Marfan and Sartans: time to wake up!Angiotensin, transforming growth factor β and aortic dilatation in Marfan syndrome: Of mice and humans.
P2860
Q26744537-E1F320D4-7C4A-4A2D-9F90-6F1126A82163Q26747739-018E7F3F-2BDD-44C5-B7E5-3C53BF9C7EBEQ37272866-AF53A85B-03EA-4C05-BB43-6347B62B516BQ37341800-1EFB6FBE-5095-45F2-AFBA-6C229CB045BCQ38607481-7FD1C9AD-A516-4820-991C-ECF6C982133DQ38745648-C69A6977-07E7-4556-BE28-052FCC44BE94Q38751533-2A35F070-43A4-4661-9FFA-13BF6AE9BB1EQ38784328-9BD1F0E6-3CD2-4584-9085-3C5B68D59625Q38930482-205E0F59-0D41-4936-89E4-92D68F07E45DQ39694748-12FB82E1-E6B7-4823-AA73-118C6328FFC3Q40085899-C856CC9F-626A-45F1-9FB7-BF852827971EQ40950687-66943E83-9F50-4706-804B-0AE94FCE9F39Q40952704-686E3AA9-D929-48D7-86B3-E4010A139C5DQ42341364-955AB2E5-0569-469F-9AB6-E6325CA7C091Q42648434-40E26341-1EF0-401C-8C6D-E0850C9D6916Q47109684-075330D6-FD37-4DE3-A627-3A9D2660EADEQ47292869-64F4C653-A8E4-4AE3-B0BD-3FDB46FD1BE1Q47751472-6E87A49E-29F2-4A7B-A32B-E55AA656EC3FQ48192119-9E643FA9-625B-4BFF-B30D-F8881C6A9161Q49134981-4527DA59-5B21-45ED-B334-A326A0EC03BFQ55266983-6ABD2137-F7B3-46D9-A8C1-B4475D104A0A
P2860
Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Beneficial Outcome of Losartan ...... 1 Mutation in Marfan Syndrome.
@en
type
label
Beneficial Outcome of Losartan ...... 1 Mutation in Marfan Syndrome.
@en
prefLabel
Beneficial Outcome of Losartan ...... 1 Mutation in Marfan Syndrome.
@en
P2093
P1476
Beneficial Outcome of Losartan ...... 1 Mutation in Marfan Syndrome.
@en
P2093
Aeilko H Zwinderman
Alessandra Maugeri
Alexander W den Hartog
Arthur J Scholte
Barbara J M Mulder
Dimitra Micha
Fleur S van Dijk
Hanne E Meijers-Heijboer
Janneke Timmermans
Maarten Groenink
P304
P356
10.1161/CIRCGENETICS.114.000950
P577
2015-01-22T00:00:00Z